Cargando…

Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma

BACKGROUND: Level 1 evidence for multimodal treatment of resectable gastric adenocarcinoma from the Intergroup 0116 (2001) and MAGIC (2006) trials demonstrated survival benefit of adjuvant chemoradiation (CRT) and perioperative chemotherapy, respectively. We evaluated the adoption of evidence-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tiffany C., Wima, Koffi, Morris, Mackenzie C., Johnston, Michael E., Shah, Shimul A., Ahmad, Syed A., Patel, Sameer H., Wilson, Gregory C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670838/
https://www.ncbi.nlm.nih.gov/pubmed/33201456
http://dx.doi.org/10.1007/s11605-020-04868-0
_version_ 1783610819495329792
author Lee, Tiffany C.
Wima, Koffi
Morris, Mackenzie C.
Johnston, Michael E.
Shah, Shimul A.
Ahmad, Syed A.
Patel, Sameer H.
Wilson, Gregory C.
author_facet Lee, Tiffany C.
Wima, Koffi
Morris, Mackenzie C.
Johnston, Michael E.
Shah, Shimul A.
Ahmad, Syed A.
Patel, Sameer H.
Wilson, Gregory C.
author_sort Lee, Tiffany C.
collection PubMed
description BACKGROUND: Level 1 evidence for multimodal treatment of resectable gastric adenocarcinoma from the Intergroup 0116 (2001) and MAGIC (2006) trials demonstrated survival benefit of adjuvant chemoradiation (CRT) and perioperative chemotherapy, respectively. We evaluated the adoption of evidence-based treatment in the post-MAGIC era and its impact on survival. METHODS: A total of 7058 patients with resectable gastric adenocarcinoma undergoing definitive surgical resection between 2004 and 2015 were analyzed using the National Cancer Database. RESULTS: Over the study period, the proportion of patients receiving adjuvant CRT decreased from 19.1% to 9.1%, while perioperative chemotherapy increased from 1.9% to 28.6%. Utilization of perioperative chemotherapy surpassed adjuvant CRT in 2011. Evidence-based treatment (either perioperative chemotherapy or adjuvant CRT) had better overall survival (OS) than other treatments for clinical stage II–III patients (p < 0.05). On multivariate analysis of the whole study period, evidence-based treatments were associated with better OS (HR 0.67 [0.60–0.74], p < 0.05). Only 360/1262 (28.5%) patients in the perioperative chemotherapy group completed postoperative therapy, which was associated with improved OS (p < 0.05). For clinical stage III patients (n = 2402), only 806 (33.6%) received evidence-based treatment, while 487 (22.2%) underwent surgery alone. On multivariate analysis of these patients between 2010 and 2015, both perioperative chemotherapy (HR 0.49 [0.35–0.68]) and adjuvant CRT (HR 0.31 [0.21–0.44]) were associated with better OS than surgery alone (p < 0.05). CONCLUSIONS: Since the INT-0116 and MAGIC trials, utilization of evidence-based treatments for resectable gastric adenocarcinoma has increased, with perioperative chemotherapy surpassing adjuvant CRT as the preferred practice. However, overall utilization of these regimens remains quite low nationally despite association with improved OS.
format Online
Article
Text
id pubmed-7670838
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-76708382020-11-18 Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma Lee, Tiffany C. Wima, Koffi Morris, Mackenzie C. Johnston, Michael E. Shah, Shimul A. Ahmad, Syed A. Patel, Sameer H. Wilson, Gregory C. J Gastrointest Surg SSAT Quick Shot Presentation BACKGROUND: Level 1 evidence for multimodal treatment of resectable gastric adenocarcinoma from the Intergroup 0116 (2001) and MAGIC (2006) trials demonstrated survival benefit of adjuvant chemoradiation (CRT) and perioperative chemotherapy, respectively. We evaluated the adoption of evidence-based treatment in the post-MAGIC era and its impact on survival. METHODS: A total of 7058 patients with resectable gastric adenocarcinoma undergoing definitive surgical resection between 2004 and 2015 were analyzed using the National Cancer Database. RESULTS: Over the study period, the proportion of patients receiving adjuvant CRT decreased from 19.1% to 9.1%, while perioperative chemotherapy increased from 1.9% to 28.6%. Utilization of perioperative chemotherapy surpassed adjuvant CRT in 2011. Evidence-based treatment (either perioperative chemotherapy or adjuvant CRT) had better overall survival (OS) than other treatments for clinical stage II–III patients (p < 0.05). On multivariate analysis of the whole study period, evidence-based treatments were associated with better OS (HR 0.67 [0.60–0.74], p < 0.05). Only 360/1262 (28.5%) patients in the perioperative chemotherapy group completed postoperative therapy, which was associated with improved OS (p < 0.05). For clinical stage III patients (n = 2402), only 806 (33.6%) received evidence-based treatment, while 487 (22.2%) underwent surgery alone. On multivariate analysis of these patients between 2010 and 2015, both perioperative chemotherapy (HR 0.49 [0.35–0.68]) and adjuvant CRT (HR 0.31 [0.21–0.44]) were associated with better OS than surgery alone (p < 0.05). CONCLUSIONS: Since the INT-0116 and MAGIC trials, utilization of evidence-based treatments for resectable gastric adenocarcinoma has increased, with perioperative chemotherapy surpassing adjuvant CRT as the preferred practice. However, overall utilization of these regimens remains quite low nationally despite association with improved OS. Springer US 2020-11-17 2021 /pmc/articles/PMC7670838/ /pubmed/33201456 http://dx.doi.org/10.1007/s11605-020-04868-0 Text en © The Society for Surgery of the Alimentary Tract 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle SSAT Quick Shot Presentation
Lee, Tiffany C.
Wima, Koffi
Morris, Mackenzie C.
Johnston, Michael E.
Shah, Shimul A.
Ahmad, Syed A.
Patel, Sameer H.
Wilson, Gregory C.
Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title_full Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title_fullStr Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title_full_unstemmed Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title_short Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma
title_sort lack of national adoption of evidence-based treatment for resectable gastric adenocarcinoma
topic SSAT Quick Shot Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670838/
https://www.ncbi.nlm.nih.gov/pubmed/33201456
http://dx.doi.org/10.1007/s11605-020-04868-0
work_keys_str_mv AT leetiffanyc lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT wimakoffi lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT morrismackenziec lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT johnstonmichaele lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT shahshimula lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT ahmadsyeda lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT patelsameerh lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma
AT wilsongregoryc lackofnationaladoptionofevidencebasedtreatmentforresectablegastricadenocarcinoma